The EU's generic drug market is shaped by four approval pathways, each with different timelines and costs. The 2025 Pharma Package reforms are accelerating market entry, but national inconsistencies still delay access for patients across Europe.
Read More
Soy Products and Thyroid Medications: Best Practices for Absorption
European Generic Markets: Regulatory Approaches Across the EU
Monitoring Your Health After Switching to Generics
Functional Impairment in Autoimmunity: How Rehab and Occupational Therapy Help You Stay Independent
mRNA Therapeutics: Side Effects and Post-Approval Monitoring
